CSL abandons $3.1 billion acquisition offer for Talecris

06/9/2009 | NYTimes.com

Australian biotech company CSL dropped its $3.1 billion bid to take over Talecris Biotherapeutics because the Federal Trade Commission opposes the deal. CSL, which makes blood plasma products, will repurchase as much as 9% of its stock for about $1.3 billion and pay Talecris $75 million for ending the offer.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY